Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1

Conditions

Multiple Myeloma 29Leukemia, Myeloid, Acute 14Recurrence 13Hodgkin Disease 12Lymphoma 11Neoplasms 10Breast Neoplasms 9Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, T-Cell, Cutaneous 6Sezary Syndrome 5Neoplasms, Plasma Cell 5Mycosis Fungoides 5Lymphoma, Mantle-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Waldenstrom Macroglobulinemia 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Immunoblastic Lymphadenopathy 4Diffuse Intrinsic Pontine Glioma 4Advanced Solid Tumors 4Primary Myelofibrosis 3

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Melanoma × Panobinostat × Clear all
NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
17 enrolled 12 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT03982134 2019-10-04

PDR001 + Panobinostat for Melanoma and NSCLC

University of Iowa

Phase 1 Withdrawn
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00925132 2017-07-02

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

University of Iowa

Phase 1/2 Terminated
39 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT01065467 2017-03-28

Panobinostat (LBH589) in Patients With Metastatic Melanoma

Dana-Farber Cancer Institute

Phase 1 Completed
16 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡